Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders.

It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders.

Braxia Scientific Corp. is headquartered in Mississauga, Ontario.